1. Signaling Pathways
  2. Anti-infection
  3. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P990756
    Pemivibart
    99.93%
    Pemivibart is an anti-SARS-CoV-2 human IgG1 λ2 monoclonal antibody. Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096).
    Pemivibart
  • HY-N8599
    Cichoriin
    Inhibitor 99.96%
    Cichoriin is an active compounds against SARS-CoV-2, and may be a potential candidate in researching severe COVID-19.
    Cichoriin
  • HY-P0012A
    Aviptadil acetate
    Inhibitor 99.87%
    Aviptadil acetate is an analog vasoactive intestinal polypeptide (VIP) with potent vasodilatory effects. Aviptadil acetate induces pulmonary vasodilation and inhibits vascular SMCs proliferation, platelet aggregation. Aviptadil acetate can be used for the research of pulmonary fibrosis, pulmonary arterial hypertension (PAH) and SARS-CoV-2 caused respiratory failure, et al.
    Aviptadil acetate
  • HY-N1739
    Tectoquinone
    Inhibitor 98.40%
    Tectoquinone (2-Methylanthraquinone) is an inhibitor for SARS CoV-2 major protease (SARS CoV-2 Mpro). Tectoquinone exhibits anti-termite and antiviral activities.
    Tectoquinone
  • HY-B1513
    α-Cyclodextrin
    99.82%
    α-Cyclodextrin (α-CD) is a soluble fiber derived from corn. α-Cyclodextrin can deplete sphingolipids and phospholipids from cell membranes. α-Cyclodextrin interacts with tubulin. α-Cyclodextrin improves defenses against SARS-CoV-2 infection. α-Cyclodextrin enhances the anticancer efficacy of Crcumin (HY-N0005) against breast, lung and cervical cancer. α-Cyclodextrin has beneficial effects on body weight and blood lipids.
    α-Cyclodextrin
  • HY-126085
    (±)-Alliin
    Inhibitor 99.58%
    (±)-Alliin is the main active component of garlic. (±)-Alliin is a putative inhibitor of the main protease of SARS-CoV-2 (Mpro).
    (±)-Alliin
  • HY-145119
    GS-621763
    Inhibitor 99.72%
    GS-621763 is an orally available precursor to GS-441524 that exhibits anti-SARS-CoV-2 viral activity in mice. GS-621763 reduces viral load to undetectable levels in ferrets infected with SARS-CoV-2.
    GS-621763
  • HY-P99810
    Quisovalimab
    Quisovalimab (AVTX-002; AEVI 002; SAR 252067) is a human monoclonal antibody against LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14) that plays an important role in acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) COVID-19. Quisovalimab can be used in COVID-19 acute respiratory distress syndrome and other studies.
    Quisovalimab
  • HY-153235
    COVID-19 Spike Protein mRNA-LNP
    COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) containing mRNA encoding COVID-19 Spike Protein. COVID-19 Spike Protein undertakes the functions of virus binding with host cell receptors, thereby mediating the entry of COVID-19 virus into cells. COVID-19 Spike Protein is an important site of action for host neutralizing antibodies and a key target for vaccine design. COVID-19 Spike Protein mRNA-LNP can be used for RNA delivery, vaccine formulation and design targeting SARS-CoV-2.
    COVID-19 Spike Protein mRNA-LNP
  • HY-B0157
    Ketotifen
    Inhibitor 99.74%
    Ketotifen (HC 20-511) is an orally active second-generation noncompetitive histamine 1 (H1) receptor blocker and mast cell stabilizer. Ketotifen can block 6-phosphogluconate dehydrogenase (PGD) in vitro. Ketotifen also has antiviral activity against SARS-CoV-2 and Influenza virus. Ketotifen can be used to the research of autoimmune encephalomyelitis (EAE) and asthma attack prevention.
    Ketotifen
  • HY-B1370R
    Hydroxychloroquine (sulfate) (Standard)
    Inhibitor 99.28%
    Hydroxychloroquine (sulfate) (Standard) is the analytical standard of Hydroxychloroquine (sulfate). This product is intended for research and analytical applications. Hydroxychloroquine sulfate (HCQ sulfate) is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine sulfate is efficiently inhibits SARS-CoV-2 infection in vitro.
    Hydroxychloroquine (sulfate) (Standard)
  • HY-108986
    JFD00244
    Inhibitor 99.40%
    JFD00244 is a sirtuin 2 (SIRT2) inhibitor, with anti-tumor effect. JFD00244 is also a Nsp-16 inhibitor against SARS-CoV-2.
    JFD00244
  • HY-10300
    Narlaprevir
    Inhibitor 98.15%
    Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a Ki value of 6 nM and an EC90 value of 40 nM. Narlaprevir also inhibits the HCV nonstructural protein 3 serine protease. Narlaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 2.3 μM.
    Narlaprevir
  • HY-156597
    Arbemnifosbuvir
    Inhibitor 99.88%
    Arbemnifosbuvir is a nidovirus DdRp-associated nucleotidyltransferase (NiRAN) domain of non-structural protein 12 (nsp12)-interfering drugs. Arbemnifosbuvir can be used for SARS-CoVs infection research.
    Arbemnifosbuvir
  • HY-157403
    Jun12682
    99.60%
    Jun12682 is an inhibitor of SARS-CoV-2 papain-like protease. Jun12682 inhibits PLpro with a Ki value of 37.7 nM. Jun12682 has EC50 value of 1.1 μM in the FlipGFP PLpro assay. Jun12682 has orally activity.
    Jun12682
  • HY-15463S
    Imatinib-d8
    Inhibitor 99.85%
    Imatinib-d8 is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity[1][2].
    Imatinib-d<sub>8</sub>
  • HY-W024485
    SARS-CoV-2-IN-86
    Inhibitor 99.35%
    SARS-CoV-2-IN-86 (Compound 2734589) is a dual inhibitor of the methyltransferases nsp14 and nsp16 of SARS-CoV-2. SARS-CoV-2-IN-86 exhibits low toxicity with a LD50 of 700 mg/kg according to toxicity analysis predict.
    SARS-CoV-2-IN-86
  • HY-B0689
    Indinavir
    Inhibitor 99.96%
    Indinavir (MK-639 free base) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir is also a SARS-CoV 3CLpro inhibitor.
    Indinavir
  • HY-P99347
    Etesevimab
    Inhibitor 98.76%
    Etesevimab (JS016) is a recombinant neutralizing human IgG1 anti-SARS-CoV-2 monoclonal antibody.
    Etesevimab
  • HY-133894
    Bofutrelvir
    Inhibitor
    Bofutrelvir (FB2001) is a SARS-CoV-2 main protease Mpro inhibitor with an IC50 value of 53 nM and an EC50 value of 0.53 μM. Bofutrelvir exhibits potent antiviral efficacy against several current SARS-CoV-2 variants with EC50 values of 0.26-0.42 μM. Bofutrelvir has an additive antiviral effect when combined with Remdesivir (HY-104077).
    Bofutrelvir
Cat. No. Product Name / Synonyms Species Source